Detalhe da pesquisa
1.
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
Lancet
; 403(10429): 838-849, 2024 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38364839
2.
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.
Ann Rheum Dis
; 83(4): 409-416, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38123338
3.
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
Ann Rheum Dis
; 82(1): 119-129, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36137735
4.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Ann Rheum Dis
; 82(1): 3-18, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36357155
5.
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Lancet
; 397(10271): 305-317, 2021 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33485455
6.
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.
Ann Rheum Dis
; 81(1): 20-33, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407926
7.
Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis.
Rheumatology (Oxford)
; 61(6): 2596-2602, 2022 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34508594
8.
First pilot study of extracellular volume MRI measurement in peripheral muscle of systemic sclerosis patients suggests diffuse fibrosis.
Rheumatology (Oxford)
; 61(4): 1651-1657, 2022 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34273164
9.
Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: an international collaborative scoping review.
Rheumatology (Oxford)
; 61(8): 3132-3148, 2022 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35094049
10.
EULAR definition of difficult-to-treat rheumatoid arthritis.
Ann Rheum Dis
; 80(1): 31-35, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33004335
11.
Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
Rheumatology (Oxford)
; 60(9): 4048-4054, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33331938
12.
Changes in the pharmacological management of rheumatoid arthritis over two decades.
Rheumatology (Oxford)
; 60(9): 4141-4151, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33404652
13.
Muscle deterioration due to rheumatoid arthritis: assessment by quantitative MRI and strength testing.
Rheumatology (Oxford)
; 60(3): 1216-1225, 2021 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32910153
14.
Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis.
Rheumatology (Oxford)
; 60(6): 2934-2945, 2021 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34080001
15.
Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
Rheumatology (Oxford)
; 60(7): 3209-3221, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33313898
16.
Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis.
Rheumatology (Oxford)
; 60(8): 3679-3688, 2021 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33432358
17.
Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition.
Int J Mol Sci
; 22(6)2021 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33809279
18.
Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis.
Ann Rheum Dis
; 79(11): 1414-1422, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32859608
19.
Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial.
Ann Rheum Dis
; 79(4): 464-471, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31996367
20.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Ann Rheum Dis
; 79(6): 685-699, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31969328